Skip to main content

Table 1 Patient characteristics

From: FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer

Characteristics

n

Percentile (%)

Sex

Female

29

45.3

Male

35

54.7

Pathology

Adenocarcinoma

61

95.3

Mucinous

3

4.7

Grade

I

4

6.3

II

57

89.1

III

3

4.7

KRAS

Wild

64

100

NRAS

Wild

64

100

Biopsy location

Primary tumour

61

95.3

Metastasis

3

4.7

Metastasis diagnosed

Synchronous

45

70.3

Metachronous

19

29.7

Right colon

Total

8

12.5

Ascending colon

5

7.8

Transverse colon

3

4.7

Left colon

Total

56

87.5

Rectum

21

32.8

Sigmoid colon

33

51.6

Descending colon

2

3.1

Metastasis location

Liver

46

71.9

Lung

7

10.9

Peritoneum

4

6.3

Bone

4

6.3

Remote lymph node

3

4.7

Metastasectomy

Yes

17

26.5

No

47

73.5

Second treatment

Yes

40

62.5

No

24

37.5

Progression

Yes

50

78.1

No

14

21.9

Death

Yes

33

51.5

No

31

48.5